CN102014907A - 外周作用阿片拮抗剂的口服给药 - Google Patents

外周作用阿片拮抗剂的口服给药 Download PDF

Info

Publication number
CN102014907A
CN102014907A CN2009801164862A CN200980116486A CN102014907A CN 102014907 A CN102014907 A CN 102014907A CN 2009801164862 A CN2009801164862 A CN 2009801164862A CN 200980116486 A CN200980116486 A CN 200980116486A CN 102014907 A CN102014907 A CN 102014907A
Authority
CN
China
Prior art keywords
opioid
opioid antagonist
therapeutically effective
peripherally
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801164862A
Other languages
English (en)
Chinese (zh)
Inventor
凯文·J·布罗德贝克
艾伦·R·库格勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of CN102014907A publication Critical patent/CN102014907A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2009801164862A 2008-05-07 2009-05-07 外周作用阿片拮抗剂的口服给药 Pending CN102014907A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12686808P 2008-05-07 2008-05-07
US61/126,868 2008-05-07
PCT/US2009/002856 WO2009137086A1 (en) 2008-05-07 2009-05-07 Oral administration of peripherally-acting opioid antagonists

Publications (1)

Publication Number Publication Date
CN102014907A true CN102014907A (zh) 2011-04-13

Family

ID=40888194

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801164862A Pending CN102014907A (zh) 2008-05-07 2009-05-07 外周作用阿片拮抗剂的口服给药

Country Status (15)

Country Link
US (1) US20110160239A1 (https=)
EP (1) EP2300009A1 (https=)
JP (1) JP2011519930A (https=)
KR (1) KR20110004425A (https=)
CN (1) CN102014907A (https=)
AU (1) AU2009244805B2 (https=)
BR (1) BRPI0912219A2 (https=)
CA (1) CA2723685C (https=)
EA (1) EA201001643A1 (https=)
IL (1) IL208794A0 (https=)
MX (1) MX2010011727A (https=)
MY (1) MY156913A (https=)
NZ (1) NZ589733A (https=)
WO (1) WO2009137086A1 (https=)
ZA (1) ZA201007531B (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104254332A (zh) * 2011-12-19 2014-12-31 萨利克斯药品有限公司 使用甲基纳曲酮口服组合物治疗和预防阿片类诱发型便秘的方法
CN104546791A (zh) * 2013-10-16 2015-04-29 辽宁亿灵科创生物医药科技有限公司 一种阿片受体拮抗剂的固体制剂及其制备方法
WO2017092638A1 (zh) * 2015-12-01 2017-06-08 江苏恒瑞医药股份有限公司 阿片样受体拮抗剂类衍生物、其制备方法及其在医药上的应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
UA123856C2 (uk) * 2010-03-11 2021-06-16 Уайт Елелсі Фармацевтичні композиції метилналтрексону та натрію додецилсульфату для перорального введення
AU2011307608B8 (en) * 2010-09-30 2015-08-27 Grünenthal GmbH Crystalline naloxol-PEG conjugate
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
LT3137081T (lt) 2014-04-28 2018-02-26 Orphomed, Inc. Buprenorfino dimeras ir jo naudojimas gydant virškinamojo trakto sutrikimus
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CN107033154B (zh) * 2016-02-02 2020-02-04 上海瀚迈生物医药科技有限公司 阿片受体拮抗剂缀合物及其应用
CN109134479A (zh) * 2017-06-27 2019-01-04 石家庄蒎格医药科技有限公司 结晶聚乙二醇纳洛酮草酸盐及制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050136031A1 (en) * 2003-12-16 2005-06-23 Bentley Michael D. Chemically modified small molecules

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
AU776567B2 (en) * 1999-11-01 2004-09-16 Evans, Brian K Composition for treatment of constipation and irritable bowel syndrome
ES2654819T3 (es) * 2001-10-18 2018-02-15 Nektar Therapeutics Conjugados poliméricos de antagonistas de opioides
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
KR101421747B1 (ko) * 2006-04-21 2014-07-30 넥타르 테라퓨틱스 모르피논의 입체선택적 환원
JP2010509227A (ja) * 2006-11-07 2010-03-25 ネクター セラピューティックス エイエル，コーポレイション オピオイド作動薬およびオピオイド拮抗薬の用量形態および同時投与

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050136031A1 (en) * 2003-12-16 2005-06-23 Bentley Michael D. Chemically modified small molecules

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ELDON ET AL: "NKTR-118 (Oral PEG-Naloxol), a PEGylated Derivative of Naloxone: Demonstration of Selective Peripheral Opioid Antagonism After Oral Administration in Preclinical Models", 《THE AMERICAN ACADEMY OF PAIN MANAGEMENT 18TH ANNUAL CLINICAL MEETING》 *
NEUMANN TA ,ET AL: "Clinical investigation of NKTR-118 as a selective oral peripheral opioid antagonist", 《THE AMERICAN ACADEMY OF PAIN MANAGEMENT 18TH ANNUAL CLINICAL MEETING》 *
PAULSON D ET AL: "Alvimopan,a novel ,peripherally-acting,mu-opioid receptor antagonist for the management of opioid-induced bowel dysfunction(OBD):Positive results from a phase III randomized,placebo-controlled,21-day trial", 《THE JOURNAL OF PAIN》 *
WEBSTER L ET AL: "A randomized,double-blind,placebo-controlled,multicenter phase IIb study to evaluate the efficacy and safety of multiple alvimopan dosage regimens for the treatment of gastrointestinal adverse events(GIAEs) associated with opioid use in subjects", 《THE JOURNAL OF PAIN》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104254332A (zh) * 2011-12-19 2014-12-31 萨利克斯药品有限公司 使用甲基纳曲酮口服组合物治疗和预防阿片类诱发型便秘的方法
CN104546791A (zh) * 2013-10-16 2015-04-29 辽宁亿灵科创生物医药科技有限公司 一种阿片受体拮抗剂的固体制剂及其制备方法
WO2017092638A1 (zh) * 2015-12-01 2017-06-08 江苏恒瑞医药股份有限公司 阿片样受体拮抗剂类衍生物、其制备方法及其在医药上的应用
CN107406456A (zh) * 2015-12-01 2017-11-28 江苏恒瑞医药股份有限公司 阿片样受体拮抗剂类衍生物、其制备方法及其在医药上的应用
CN107406456B (zh) * 2015-12-01 2019-08-30 江苏恒瑞医药股份有限公司 阿片样受体拮抗剂类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
CA2723685A1 (en) 2009-11-12
MY156913A (en) 2016-04-15
EP2300009A1 (en) 2011-03-30
BRPI0912219A2 (pt) 2015-10-06
MX2010011727A (es) 2010-11-30
EA201001643A1 (ru) 2011-06-30
AU2009244805A1 (en) 2009-11-12
ZA201007531B (en) 2012-03-28
AU2009244805B2 (en) 2013-01-10
IL208794A0 (en) 2010-12-30
WO2009137086A1 (en) 2009-11-12
US20110160239A1 (en) 2011-06-30
NZ589733A (en) 2012-07-27
CA2723685C (en) 2016-09-27
KR20110004425A (ko) 2011-01-13
JP2011519930A (ja) 2011-07-14

Similar Documents

Publication Publication Date Title
CA2723685C (en) Oral administration of peripherally-acting opioid antagonists
US20190388430A1 (en) Opioid and antiemetic combination compositions for increased pain relief
KR101545874B1 (ko) 난용성 약물의 전달을 위한 입상 조성물
US20030191147A1 (en) Opioid antagonist compositions and dosage forms
JP2004515455A (ja) オピオイドアンタゴニスト組成物および投薬形態
US20160106680A1 (en) Abuse Deterrent Immediate Release Formulation
EP1450824A1 (en) Pharmaceutical composition
WO2012056402A2 (en) Formulations and methods for attenuating respiratory depression induced by opioid overdose
AU2001259458B2 (en) Opioid antagonist compositions and dosage forms
US20180228797A1 (en) Pharmaceutical compositions
AU2014233453A1 (en) Compositions with a rheological modifier to reduce dissolution variability
AU2001259458A1 (en) Opioid antagonist compositions and dosage forms
EP2968178B1 (en) Pharmaceuticals comprising a ph-dependent component and ph-raising agent
HK1210959A1 (en) Use of opioid receptor antagonist for gastrointestinal tract disorders
US20250345324A1 (en) Combination formulations of naloxone and atipamezole
US20210085672A1 (en) Oral tablet formulations
AU2019201397A1 (en) Formulations and methods for attenuating respiratory depression induced by opioid overdose
US20160256453A1 (en) Opioid receptor antagonist for use in treating patients with severe constipation induced by high opiate dosage regimen

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110413